The cell and gene supply chain is a critical component of the biotechnology industry, involving the production and distribution of high-value biological materials such as cells, genes, and other biomolecules. The supply chain includes various stakeholders, including cell banks, biomanufacturers, distributors, and research institutions, which work together to ensure the quality, safety, and availability of these biological materials. The supply chain is complex and vulnerable to disruptions, with potential impacts on product efficacy, patient care, and public health. To mitigate these risks,

The cell and gene supply chain is a critical component of the biotechnology industry, involving the production and distribution of high-value biological materials such as cells, genes, and other biomolecules. The supply chain includes various stakeholders, including cell banks, biomanufacturers, distributors, and research institutions, which work together to ensure the quality, safety, and availability of these biological materials. The supply chain is complex and vulnerable to disruptions, with potential impacts on product efficacy, patient care, and public health. To mitigate these risks,

Germline cells are important but extremely delicate plant, animal, and human cells whose genetic composition contains DNA from all of their generations. Now, these cells can be altered using the potent CRISPR/Cas9 gene-editing method. The novel method focuses on the RNA-based expression of specific genes in germ cells. A recent study published in the journal Molecular Cell suggests that this molecular "CRISPR-on-a-chip" assay may even be useful against the relatively old retroviruses that cause cystic fibrosis in some individuals.

Though it should be made clear that this is not a method